The ASO strategy was recently tested in an experimental mouse model of HCS termed Notch2tm1.1Ecan and characterized by a NOTCH2 gain-of-function and severe osteopenia secondary to increased osteoclastogenesis (Canalis et al., 2020). The gene discussed is NOTCH2; the disease is Osteopenia.